Key Differences Explained
The intersection of chronic pain and addiction is a clinical minefield. An estimated 21-29% of patients prescribed opioids for chronic pain develop opioid use disorder (NIDA). These patients face a cruel paradox: their pain is real, but the medications that relieve it can kill them.
Chronic pain + addiction requires specialized integrated treatment. Simply removing opioids without addressing pain guarantees relapse — untreated pain is the number one relapse trigger in this population. The treatment approach uses: buprenorphine (Suboxone) which uniquely treats BOTH opioid addiction and chronic pain, non-opioid medications (gabapentin, duloxetine, topical lidocaine), interventional procedures (nerve blocks, spinal cord stimulation), physical therapy, and psychological approaches (CBT for pain, acceptance and commitment therapy).
Addiction without chronic pain follows standard treatment protocols without the added complexity of ongoing pain management. MAT, therapy, and peer support address the addiction directly.
The Buprenorphine Advantage
For patients with both conditions, buprenorphine is often the ideal medication — it treats opioid addiction (prevents withdrawal and cravings) while providing genuine analgesic effect for pain. Doses may need to be higher than standard addiction doses (split into 3-4x daily for pain coverage). This dual benefit makes Suboxone preferable to Vivitrol in chronic pain patients.